Iloprost improves gas exchange in patients with pulmonary hypertension and ARDS.
OBJECTIVE
We hypothesized that nebulized iloprost would improve ventilation-perfusion matching in patients with pulmonary hypertension and ARDS as reflected by an improved Pao2/Fio2 ratio and Pao2 without adversely affecting lung mechanics or systemic hemodynamics.


METHODS
Patients with ARDS and pulmonary hypertension were enrolled. With constant ventilator settings, hemodynamics, airway pressures, and gas exchange measured at baseline were compared with values 30 min after administration of 10 μg nebulized iloprost, and again 30 min after a second, larger, 20 μg dose of iloprost, and then a final measurement 2 h after the second dose. The primary outcome variable was Pao2; secondary outcomes were Pao2/Fio2 ratio, mean arterial BP, and lung-compliance ventilatory equivalents for oxygen and CO2.


RESULTS
After informed consent was obtained, 20 patients (nine men, 11 women; median age, 59 years [interquartile range, 44-66 years]) with ARDS were enrolled. Baseline PaO2 improved from a mean (±SD) of 82 (13) mm Hg to 100 (25) mm Hg after both the first and second doses of iloprost, and the baseline mean (±SD) PaO2/FIO2 ratio of 177 (60) improved to 213 (67) and 212 (70) (all P<.01). PaCO2, peak and plateau airway pressures, systemic BP, and heart rate were not significantly changed after iloprost.


CONCLUSIONS
The improvement in gas exchange without any detrimental effects on pulmonary mechanics or systemic hemodynamics suggests nebulized iloprost may be a useful therapeutic agent to improve oxygenation in patients with ARDS.


BACKGROUND
ClinicalTrials.gov; No.: NCT01274481; URL: www.clinicaltrials.gov.
Division of Pulmonary and Critical Care Medicine, University of Oklahoma Health Sciences, Oklahoma City, OK.
Eva
E
Sawheny
Division of Pulmonary and Critical Care Medicine, University of Oklahoma Health Sciences, Oklahoma City, OK.
Ashley L
AL
Ellis
Division of Pulmonary and Critical Care Medicine, University of Oklahoma Health Sciences, Oklahoma City, OK. Electronic address: Gary-Kinasewitz@ouhsc.edu.
Gary T
GT
Kinasewitz
D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D005260:Female; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D016285:Iloprost / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011659:Pulmonary Gas Exchange / Q000187:drug effects / Q000502:physiology*; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D015656:Respiratory Mechanics / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D014665:Vasodilator Agents; D016285:Iloprost